Related Experiment Video

Updated: Apr 28, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

ABCA1 rs4149313 polymorphism and susceptibility to coronary heart disease: a meta-analysis

Shu-Li Fan1, Xu Li, Si-Jiao Chen

  • 1Department of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang, 110001, P.R. China.

Annals of Human Genetics
|June 20, 2014
PubMed

Insights

The ABCA1 rs4149313 gene variant is linked to a higher risk of coronary heart disease (CHD). This risk is particularly significant in Asian populations, according to a comprehensive meta-analysis.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology

Background:

  • Common polymorphisms in the ABCA1 gene are implicated in coronary heart disease (CHD) development.
  • Previous individual study results on the ABCA1 rs4149313 polymorphism and CHD risk are inconclusive.

Purpose of the Study:

  • To conduct a meta-analysis to precisely estimate the association between the ABCA1 rs4149313 polymorphism and CHD risk.
  • To investigate potential ethnic differences in this association.

Main Methods:

  • A systematic literature search was performed across multiple databases up to September 1, 2013.
  • Meta-analysis was conducted using STATA 12.0, calculating odds ratios (OR) and 95% confidence intervals (CI).
  • Eleven case-control studies comprising 5416 CHD patients and 20,897 controls were included.

Main Results:

  • The ABCA1 rs4149313 polymorphism was associated with an increased risk of CHD.
  • Subgroup analysis revealed a significant association in Asian populations but not in Caucasian populations.
  • Meta-regression indicated ethnicity as a primary source of heterogeneity.

Conclusions:

  • The ABCA1 rs4149313 polymorphism may contribute to CHD risk.
  • The association appears stronger in Asian populations compared to Caucasian populations.
  • Ethnicity is a crucial factor influencing the relationship between this polymorphism and CHD risk.

Keywords:
ABCA1coronary heart diseasemeta-analysispolymorphismsusceptibility

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

14.4K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81